CD33 and acute myeloid leukemia: A study in Acute Myeloid Leukemia (AML) patients treated with gemtuzumab ozogamicin, a CD33 conjugate to calicheamicin, showed a link between alternative splicing of the CD33 antigen and clinical response [18], while an increased expression of a CD19 isoform with intraexonic splicing of exon 2 was found associated with treatment failure on blinatumomab [19].